IMU-856 is a novel, orally available small molecule aiming at a yet undisclosed target which was identified to be involved in the initiation and relapse of inflammatory bowel diseases (IBD). The mechanism of action targets the restoration of the intestinal barrier function in IBD patients. This concept avoids suppression of the immune functions and should therefore maintain immune surveillance for patients.
IMU-856 is currently in preclinical testing. Immunic expects IMU-856 to enter clinical trials in H1 2020. In November 2018, Tokyo-based Daiichi Sankyo Co., Ltd. granted Immunic the exclusive right to license the development program.